Figure 4. Targeting the NF-κB pathway.

This Figure reports those drugs that have been shown to modulate NF-κB in Ph⁺ leukemias. In particular, NF-κB signaling can be modulated by IKK inhibitors (such as PS1145, BAY11-67082, AS602868), proteasome inhibitors (Bortezomid) or with drugs able to act at the transcriptional level (alantolactone, parthenolide).